ClinicalTrials.gg
Not yet recruitingNCT07858331PIVOTUpdated Oct 5, 2026

Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access

A Phase 4 interventional study of Semaglutide and Virtual Weight Management Coaching in Obesity, Chronic Kidney Disease and Chronic Renal Disease, sponsored by Kristin Clemens. Not yet recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Kristin Clemens · Phase 4, Interventional, and Treatment

How we know · 4 judgments

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
880
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 145 studies testing semaglutide in Obesity — 70 open to participants now, 79 under way, 15 of them phase 3. Semaglutide · Obesity.

Planned enrollment
8th of 145
880 · median 100
Started
2027
with 5 others
Phase 4
40 of 145
20 open now
Primary completion
2029-01
later than 68 of 78 live
Registered
139th of 145
by date

Among the 145 studies testing semaglutide in Obesity, this one is the 8th largest by planned enrollment, is one of 6 that started in 2027, is one of 40 in phase 4, reaches primary completion later than 68 of the 78 other live ones, and was the 139th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

70 of the 145 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

65 more — sign in →

By country, each count listing its studies:

All 70 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

Obesity has a serious impact on people's health and quality of life. For those with advanced kidney disease (i.e. approaching the need for dialysis), obesity is especially problematic - obesity can not only lead to worsening kidney function and kidney failure, but it can also prevent patients from receiving a lifesaving kidney transplantation due to concerns about operation risks. Unfortunately, there is an urgent need but no rigorously proven treatments to help people with advanced kidney disease lose weight effectively and safely.

The investigative team is a large team of doctors, nurses, dieticians, exercise specialists, social scientists, and patients with a lived experience, have spent three years advancing research to help people with advanced kidney disease achieve a healthier body weight. They have created a special weight loss program that combines individualized coaching on diet and save activity with a medication proven to help people with healthier kidneys lose weight (i.e. Ozempic). This research program is called PIVOT: Patient-centred Intervention with Virtual support for Obesity and kidney Transplant access.

The investigators have started to test PIVOT in a small pilot study and early results show that there is potential to study the program on a much larger scale (i.e. across Canada). With funding from CIHR, the investigators aim to reach more Canadians with advanced kidney disease (including people of lower income, women, and people of different races) with an aim of helping them lose weight safely, feel better, obtain a kidney transplant, and staying healthier over the longer term.

03

Conditions studied

  • Obesity
  • Chronic Kidney Disease
  • Chronic Renal Disease
  • CKD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • >35 kg/m2
  • \<15ml/min/1.73m2 at baseline OR 2-year KFRE2 of 10% or greater

Exclusion criteria

Exclusion Criteria:

  • Known to a GLP-1RA (pancreatitis, personal or family history of medullary thyroid cancer, , pregnancy, breastfeeding)
  • Type 1 diabetes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
880 participants (estimated)

Study arms

  • Experimental
    Virtual Weight Management Program

    A maximum tolerated dose of semaglutide will be administered once weekly subcutaneously, up to a dose of 2.0 mg. Participants will also receive nutritional and movement advice, as well as virtual coaching once every 4 weeks for 6 months.

    Drug: Semaglutide · Behavioral: Virtual Weight Management Coaching

  • No intervention
    Usual Care

    Usual care participants will continue to receive the typical standard of kidney and diabetes care. They will not receive any study medication or coaching.

Interventions

  • Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.

    Also known as: Wegovy, Ozempic, Generic Semaglutide, Apo-Semaglutide, Semaglutide Injection

  • BehavioralVirtual Weight Management Coaching

    Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.

    Also known as: Coaching, Weight Management

06

What researchers measure

Primary outcomes

  1. Change in Body Weight

    Continuous measure of weight in kilograms assessed on calibrated clinic scales (dry weight for those receiving dialysis given fluid shifts)

    Time frame: Baseline to 26 weeks +/- 14 days

Secondary outcomes

  1. Quality of Life - Kidney Disease Quality of Life 36-Item Short Form

    Change in Kidney Disease Quality of Life (KDQOL-36) score across treatment arms. KDQOL-36 is scored on a 0-100 scale across five domains, with higher scores indicating better health-related quality of life.

    Time frame: Baseline to 26 weeks +/- 14 days

  2. Health-Related Quality of Life - European Quality of Life 5 Dimensions, 5 Level (EQ-5D-5L) Questionnaire

    Change in health-related quality of life measured using the European Quality of Life 5-Dimension, 5-Level questionnaire across treatment arms. A score of 11111 = no problems in any dimension (best), and a score of 55555 = extreme problems in all dimensions (worst).

    Time frame: Baseline to 26 weeks +/- 14 days

  3. Change in Functional Status - Kidney Disease Quality of Life 36-Item Short form (KDQOL-36)

    Change in functional status measured with KDQOL-36™ scores across treatment arms. KDQOL-36 is scored on a 0-100 scale across five domains, with higher scores indicating better health-related quality of life.

    Time frame: Baseline to 26 weeks +/- 14 days

  4. Change in Functional Status - European Quality of Life five-dimensional, five-level generic measure (EQ-5D-5L) scores across treatment arms.

    Measured via EQ-5D-5L (European Quality of Life five-dimensional, five-level generic measure) scores across treatment arms. A score of 11111 = no problems in any dimension (best), and a score of 55555 = extreme problems in all dimensions (worst).

    Time frame: Baseline to 26 weeks +/- 14 days

  5. Weight Loss ≥5%

    Percentage of participants achieving at least 5% reduction in body weight from baseline.

    Time frame: Baseline to 26 weeks +/- 14 days

  6. Weight Loss ≥10%

    Percentage of participant achieving at least 10% reduction in body weight from baseline.

    Time frame: Baseline to 26 weeks +/- 14 days

  7. Weight Loss ≥15%

    Percentage of participants achieving at least 15% reduction in body weight from baseline.

    Time frame: 26 weeks +/- 14 days

  8. Weight Loss ≥20%

    Percentage of participants achieving at least 20% reduction in body weight from baseline.

    Time frame: Baseline to 26 weeks +/- 14 days

  9. Body Mass Index (BMI)

    Change in BMI across treatment arms. Measured in kg/m²

    Time frame: Baseline to 26 weeks +/- 14 days

  10. Body Surface Area (BSA)

    Change in BSA across treatment arms. Measured in m².

    Time frame: Baseline to 26 weeks +/- 14 days

  11. Body Mass Index <35 kg/m²

    Percentage of participants achieving a BMI below \<35 kg/m², corresponding to the specified weight-based threshold for transplant listing.

    Time frame: Week 26 +/- 14 days

  12. Dalhousie Clinical Frailty Scale Rating

    Change in Dalhousie Clinical Frailty Scale rating across treatment arms. The scale ranges from 1 (very fit) to 9 (terminally ill).

    Time frame: Baseline to 26 weeks +/- 14 days

  13. SARC-F Score

    Change in sarcopenia measured by SARC-F score across treatment arms. This questionnaire is scored out of 10, with a score of 4 or higher indicating probable sarcopenia.

    Time frame: Baseline to 26 weeks +/- 14 days

  14. FRAIL Scale

    Change in frailty measured by the FRAIL Scale across treatment arms. The scale scores five components - fatigue, resistance, ambulation, illnesses, and loss of weight - on a 0-5 scale, with 0 indicating robust, 1-2 pre-frail, and 3 or more indicating frailty.

    Time frame: Baseline to 26 weeks +/- 14 days

  15. Acute Kidney Injury (AKI)

    Incidence of AKI. AKI defined by KDIGO as creatinine ≥ 1.5x baseline within 7 days in non-dialysis participants

    Time frame: Baseline to 26 weeks +/- 14 days

  16. Hypoglycemia

    Incidence of hypoglycemia (blood glucose \<4 mmol/L or time below target using continuous glucose monitoring)

    Time frame: Baseline to week 26 +/- 14 days

  17. Gastrointestinal Symptoms

    Incidence of gastrointestinal symptoms, including nausea, vomiting, constipation

    Time frame: Baseline to 26 weeks +/- 14 days

  18. Acute Biliary Disease

    Incidence of acute biliary disease.

    Time frame: Baseline to 26 weeks +/- 14 days

  19. Acute Pancreatitis

    Incidence of acute pancreatitis.

    Time frame: Baseline to 26 weeks +/- 14 days

  20. Diabetic Retinopathy Interventions

    Incidence of interventions for diabetic retinopathy

    Time frame: Baseline to 26 weeks +/- 14 days

  21. Injection-site reactions

    Incidence of injection-site reactions in the intervention arm.

    Time frame: Baseline to 26 weeks +/- 14 days

  22. Malignant Neoplasms

    Incidence of malignant neoplasms.

    Time frame: Baseline to 26 weeks +/- 14 days

  23. Coaching Visit Adherence

    Percentage of participants completing ≥4 of 6 coaching visits.

    Time frame: Baseline to 26 weeks +/- 14 days

  24. Semaglutide Discontinuation

    Percentage of participants discontinuing semaglutide in the intervention arm.

    Time frame: Baseline to 26 weeks +/- 14 days

  25. Achievement of semaglutide dose ≥1.0 mg/week

    Percentage of participants in the intervention group achieving a semaglutide dose of ≥1.0 mg/week.

    Time frame: Week 26 +/- 14 days

  26. Achievement of Semaglutide Dose ≥2.0 mg/week

    Percentage of participants achieving a semaglutide dose of ≥2.0 mg/week

    Time frame: 26 weeks +/- 14 days

  27. Semaglutide Initiation in Usual Care

    Percentage of usual care arm participants initiating semaglutide during the study period.

    Time frame: Baseline to 26 weeks +/- 14 days

  28. Use of Semaglutide in Usual Care Participants

    Percentage of participants using semaglutide in the usual care arm.

    Time frame: Baseline to 26 weeks +/- 14 days

  29. Semaglutide Dose ≥1.0 mg/Week in Usual care Arm

    Percentage of usual care participants achieving semaglutide dose ≥1.0 mg/week

    Time frame: 26 weeks +/- 14 days

  30. Semaglutide Dose ≥2.0 mg/Week in Usual Care Arm

    Percentage of usual care participants achieving semaglutide dose ≥2.0 mg/week

    Time frame: 26 Weeks +/- 14 days

  31. Body Fat Percentage Measured with Smart Scale

    Change in body fat percentage among the subsample of intervention participants using the study smart scale.

    Time frame: Baseline to 26 weeks +/- 14 days

  32. Muscle Mass Measured with Smart Scale

    Measured in kilograms. Change in muscle mass among the subsample of intervention participants using the study smart scale.

    Time frame: Baseline to 26 weeks +/- 14 days

  33. Intervention Costs

    The total cost of the intervention incurred by participants during the 26-week follow-up period, in Canadian dollars (CAD)

    Time frame: Baseline to 26 weeks

  34. Out-of-pocket costs

    Total out-of-pocket costs incurred by participants during the 26-week study period-including costs directly related to the intervention. Measured in Canadian dollars (CAD)

    Time frame: Baseline to 26 weeks

  35. Lost Productivity Costs

    Costs associated with productivity losses during the 26-week follow-up period, including costs directly related to the participant's health care and intervention. Measured in Canadian dollars (CAD)

    Time frame: Baseline to 26 weeks

  36. Health care utilization costs

    Total costs associated with health care utilization during the study period, including physician visits, hospitalizations, emergency department visits, medications, allied health services. Measured in Canadian dollars (CAD) using provincial administrative health data.

    Time frame: Baseline to 26 weeks

Other outcomes

  1. Change in HbA1c

    Change in glycated hemoglobin among participants with diabetes across treatment arms.

    Time frame: Baseline to 24 Months

  2. Hospitalization for Hyperglycemia

    Incidence of hospitalization for hyperglycemia in participants with diabetes across treatment arms

    Time frame: Baseline to 24 Months

  3. Hospitalization for hypoglycemia

    Incidence of hospitalization for hypoglycemia in participants with diabetes across treatment arms.

    Time frame: Baseline to 24 Months

  4. Initiation of Dialysis

    Percentage of non-dialysis participants initiating dialysis across treatment arms

    Time frame: Baseline to 24 Months

  5. Cardiovascular Composite

    Composite of hospitalization for acute myocardial infarction, stroke, amputation, or heart failure across treatment arms.

    Time frame: Baseline to 24 Months

  6. Kidney Transplantation

    Percentage of participants receiving kidney transplantation across treatment arms.

    Time frame: Baseline to 24 months

  7. Healthcare utilization

    Health care utilization over 24 months including number of hospital admissions, emergency department, outpatient and primary care visits, specialist visits, rehabilitation, allied health care visits. Measured using provincial administrative health data.

    Time frame: 24 months

  8. Health care costs

    Health care costs over 24 months, including total health care costs, hospitalization-related costs, emergency department costs, outpatient and physician costs, medication costs. Measured in Canadian dollars (CAD) using provincial administrative health data.

    Time frame: 24 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 24 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2026
First posted
Oct 5, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jan 1, 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858331
Lead sponsor
Kristin Clemens
Responsible party
Kristin Clemens (Dr., Western University, Canada) — Sponsor-investigator
First posted
Oct 5, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 1, 2029 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Heather LaPier
Contact
heather.lapier@sjhc.london.on.ca
519-646-6100 ext. 65373
Kristin Clemens, MD
principal investigator · St. Joseph's Health Care London, Western University
Louise Moist, MD
principal investigator · London Health Sciences Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion